GENELUX Corp
Genelux (Nasdaq: GNLX) is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for patients with aggressive or difficult-to-treat cancers. Its lead product candidate, Olvi-Vec, is a modified vaccinia virus designed to selectively kill tumor cells and stimulate an immune response; it is… From the company’s description.
Over the twelve months to Jun 30, 2026, GENELUX Corp reported revenue of $0.01M and a net loss of $35.60M. Operations used $25.28M in cash. In fiscal 2025, it reported revenue of $0.01M, about the same as fiscal 2024, and a net loss of $32.15M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What GENELUX Corp does
In the company’s own words
Genelux (Nasdaq: GNLX) is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for patients with aggressive or difficult-to-treat cancers. Its lead product candidate, Olvi-Vec, is a modified vaccinia virus designed to selectively kill tumor cells and stimulate an immune response; it is being evaluated in ovarian and lung cancer trials. The company’s CHOICE discovery platform supports the development of engineered vaccinia-virus candidates, with more than 500 versions incorporating over 110 transgenes. Genelux has one business focused on research, development and manufacturing, rather than separately reported operating segments. Its clinical program includes a Phase 3 trial for platinum-resistant or refractory ovarian cancer and Phase 2 and Phase 1b/2 trials for recurrent non-small cell and small cell lung cancers, respectively. A China-based partner holds exclusive regional rights to develop and commercialize Olvi-Vec and other licensed products in mainland China, Taiwan, Hong Kong and Macau. Genelux operates a cGMP manufacturing facility in San Diego to supply clinical trials and support potential commercial production. Its website is www.genelux.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WESTLAKE VILLAGE, CA
- Fiscal year end
- December
- CIK
- 1231457
- SIC
- 2834
Financial performance, year by year
Fiscal 2023–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns GENELUX Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · GENELUX Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do GENELUX Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of GENELUX Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in GENELUX Corp's last four quarterly filings that the numbers alone won't show?”